Send to

Choose Destination
PLoS One. 2020 Feb 28;15(2):e0229075. doi: 10.1371/journal.pone.0229075. eCollection 2020.

miRNA profiling in renal carcinoma suggest the existence of a group of pro-angionenic tumors in localized clear cell renal carcinoma.

Author information

Biomedica Molecular Medicine SL, Madrid, Spain.
Urology Service, Hospital Universitario 12 de Octubre, Madrid, Spain.
Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain.
Molecular Oncology and Pathology Lab, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
Clínica Internacional S.A., Lima, Perú.
Urology Department, Clínica Universidad de Navarra, Madrid, Spain.
Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Madrid, Spain.
Medical Oncology Service, La Paz University Hospital-IdiPAZ, Madrid, Spain.


Renal cell carcinoma comprises a variety of entities, the most common being the clear-cell, papillary and chromophobe subtypes. These subtypes are related to different clinical evolution; however, most therapies have been developed for clear-cell carcinoma and there is not a specific treatment based on different subtypes. In this study, one hundred and sixty-four paraffin samples from primary nephrectomies for localized tumors were analyzed. MiRNAs were isolated and measured by microRNA arrays. Significance Analysis of Microarrays and Consensus Cluster algorithm were used to characterize different renal subtypes. The analyses showed that chromophobe renal tumors are a homogeneous group characterized by an overexpression of miR 1229, miR 10a, miR 182, miR 1208, miR 222, miR 221, miR 891b, miR 629-5p and miR 221-5p. On the other hand, clear cell renal carcinomas presented two different groups inside this histological subtype, with differences in miRNAs that regulate focal adhesion, transcription, apoptosis and angiogenesis processes. Specifically, one of the defined groups had an overexpression of proangiogenic microRNAs miR185, miR126 and miR130a. In conclusion, differences in miRNA expression profiles between histological renal subtypes were established. In addition, clear cell renal carcinomas had different expression of proangiogenic miRNAs. With the emergence of antiangiogenic drugs, these differences could be used as therapeutic targets in the future or as a selection method for tailoring personalized treatments.

Conflict of interest statement

JAFV, EE and AG-P are shareholders in Biomedica Molecular Medicine SL. LT-F, GP-V, AZ-M and EL-C are employees of Biomedica Molecular Medicine SL. GDV received personal fees from BMS; Roche, Novartis, Pfizer, MSD; Bayer, Astellas, Ipsen, Janssen, and SEOM and reports grants from Roche, Ipsen, and Pfizer. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center